UroGen Pharma Ltd [NASDAQ: URGN] jumped around 0.95 points on Friday, while shares priced at $12.03 at the close of the session, up 8.57%.
Compared to the average trading volume of 2.05M shares, URGN reached a trading volume of 19322104 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about UroGen Pharma Ltd [URGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for URGN shares is $35.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on URGN stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for UroGen Pharma Ltd shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 22, 2025. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on April 16, 2025, representing the official price target for UroGen Pharma Ltd stock. Previously, the target price had yet another raise to $31, while Ladenburg Thalmann analysts kept a Buy rating on URGN stock.
The Average True Range (ATR) for UroGen Pharma Ltd is set at 1.44, with the Price to Sales ratio for URGN stock in the period of the last 12 months amounting to 6.04.
How has URGN stock performed recently?
UroGen Pharma Ltd [URGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 63.23. With this latest performance, URGN shares gained by 21.88% in over the last four-week period, additionally sinking by -0.08% over the last 6 months – not to mention a drop of -8.10% in the past year of trading.
#####
UroGen Pharma Ltd [URGN]: Deeper insight into the fundamentals
UroGen Pharma Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.47 and a Current Ratio set at 5.65.
Insider trade positions for UroGen Pharma Ltd [URGN]
The top three institutional holders of URGN stocks are: RTW INVESTMENTS, LP with ownership of 3.56 million shares, which is approximately 9.661%. ADAGE CAPITAL PARTNERS GP, L.L.C., holding 3.3 million shares of the stock with an approximate value of $$55.37 million in URGN stocks shares; and ADAGE CAPITAL PARTNERS GP, L.L.C., currently with $$51.74 million in URGN stock with ownership which is approximately 8.3739%.
